{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:02:04Z","timestamp":1784984524837,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tstp20221158"],"award-info":[{"award-number":["tstp20221158"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqnz20221164"],"award-info":[{"award-number":["tsqnz20221164"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203000"],"award-info":[{"award-number":["82203000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073200"],"award-info":[{"award-number":["82073200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH300"],"award-info":[{"award-number":["ZR2022QH300"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2025.12.048","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:51:32Z","timestamp":1767891092000},"page":"863-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Radiation Therapy With Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study"],"prefix":"10.1016","volume":"125","author":[{"given":"Zhaohan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-1774","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.048_bib0001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0002","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer","volume":"40","author":"Scott","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0007","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0008","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0009","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0010","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0011","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0012","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0013","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: The dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0014","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0015","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0016","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3748\/wjg.v23.i14.2470","article-title":"Biliary tract cancer stem cells - translational options and challenges","volume":"23","author":"Mayr","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0017","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ijrobp.2022.03.019","article-title":"The combination of radiation therapy and immunotherapy is effective and well-tolerated for unresectable biliary tract cancer","volume":"113","author":"Chen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","article-title":"Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade","volume":"7","author":"Liu","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0021","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jnci\/djad046","article-title":"Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma","volume":"115","author":"Spencer","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0022","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41416-021-01438-2","article-title":"TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma","volume":"125","author":"Casey","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0023","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.7150\/thno.96322","article-title":"Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"14","author":"Slootbeek","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0024","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s40478-014-0174-y","article-title":"WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma","volume":"2","author":"Zhukova","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0167-8140(96)01806-3","article-title":"The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy","volume":"40","author":"Bristow","year":"1996","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0026","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00000658-199506000-00017","article-title":"Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival","volume":"221","author":"Pitt","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0027","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000530134","article-title":"Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases","volume":"12","author":"De","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0028","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12916-024-03381-4","article-title":"Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"Zhu","year":"2024","journal-title":"BMC Med"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2025.12.048_bib0029","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/liv.14098","article-title":"The tumour microenvironment and immune milieu of cholangiocarcinoma","volume":"39","author":"Fabris","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0030","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.4049\/jimmunol.163.4.2314","article-title":"The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns","volume":"163","author":"Doherty","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0031","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0032","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.3390\/ijms20133212","article-title":"Tumor microenvironment as a \u201cGame Changer\u201d in cancer radiotherapy","volume":"20","author":"Jarosz-Biej","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0033","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: Relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011061","article-title":"The abscopal effect: A review of pre-clinical and clinical advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0035","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update","volume":"61","author":"Khan","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e20665","article-title":"Sequence of stereotactic ablative radiotherapy and immune checkpoint blockade in the treatment of metastatic lung cancer","volume":"35","author":"Pinnamaneni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0037","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.013","article-title":"Concurrent chemoradiation \u00b1 atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology\/Alliance LU005","volume":"120","author":"Higgins","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0038","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","article-title":"HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF","volume":"19","author":"Rolny","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fonc.2019.00156","article-title":"Novel approaches to improve the efficacy of immuno-radiotherapy","volume":"9","author":"Shevtsov","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.048_bib0041","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.trsl.2017.11.002","article-title":"The role of macrophage phenotype in regulating the response to radiation therapy","volume":"191","author":"Shi","year":"2018","journal-title":"Transl Res"},{"issue":"suppl 15","key":"10.1016\/j.ijrobp.2025.12.048_bib0042","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2020.38.15_suppl.3018","article-title":"Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy: A US Food and Drug Administration pooled analysis","volume":"38","author":"Anscher","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:29:28Z","timestamp":1784982568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0360301626000143"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.048","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated Radiation Therapy With Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}